A new Periodic Transaction Report filed with the U.S. House of Representatives shows Hon. Gilbert Cisneros purchased shares of Alkermes plc (ALKS) on July 30, 2026. The transaction, made personally by the member of Congress, falls within the $15,001 to $50,000 disclosure range required under the STOCK Act. Our internal tracking system classifies this filing as a congress buy signal, meaning Cisneros added to a position rather than trimming or exiting one.
The holding is disclosed as being held through 150 Main Street Trust, with Bank of America listed as the brokerage of record. Members of Congress frequently hold assets through trusts or managed accounts, and the STOCK Act requires disclosure of these transactions within a set window regardless of the account structure used.
An Insider Sale on the Other Side of the Ledger
What makes this filing notable is its proximity to a separate transaction involving Alkermes itself. Company insider Gaffin David Joseph sold ALKS shares on August 3, 2026, in a transaction valued at $98,812. That sale landed within 30 days of Cisneros’s congressional purchase, placing a member of Congress buying into the stock on one side of a narrow window and a corporate insider selling out of it on the other.
There is nothing in the public record to suggest these two transactions are connected, and STOCK Act disclosures are a legal requirement for members of Congress, not an indication of wrongdoing. Insider sales by corporate executives are also routine and often tied to compensation schedules, tax planning, or diversification rather than any view on near-term performance. Still, the timing overlap is the kind of pattern that whoisbuyingnow.com exists to surface for readers who track both congressional and corporate insider activity side by side.
Alkermes plc is a biopharmaceutical company, and its shares can see price movement around clinical trial updates, regulatory decisions, and earnings reports. Congressional purchases in healthcare and biotech names tend to draw attention precisely because lawmakers sometimes have visibility into policy or regulatory developments before the broader public does, though this filing alone does not establish any such connection.
Readers who follow institutional positioning alongside congressional trades may also want to see how larger funds have approached similar biotech names. Our quarterly tracking of Renaissance Technologies LLC’s 13F portfolio moves offers a comparison point for how large quantitative funds have adjusted healthcare exposure over recent quarters.
As always, this report reflects only what has been disclosed in the public filing. Further amendments, if any, will be reflected in updated coverage as they become available.